Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT

Targeted Oncology

Volumn 9, Issue 4, 2014, Pages 339-347

  Boers Sonderen, Marye J ^a   de Geus Oei, Lioe Fee ^a   Desar, Ingrid M E ^a   van der Graaf, Winette T A ^a   Oyen, Wim J G ^a   Ottevanger, Petronella B ^a   van Herpen, Carla M L ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Mammalian target of rapamycin; Pegylated liposomal doxorubicin; Temsirolimus

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ASPARTATE AMINOTRANSFERASE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GAMMA GLUTAMYLTRANSFERASE; LACTATE DEHYDROGENASE; TEMSIROLIMUS; ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG UPTAKE; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; ENDOMETRIUM CANCER; EPISTAXIS; FAINTNESS; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLYCOLYSIS; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; ILEUS; INFECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; METABOLIC PARAMETERS; METABOLIC VOLUME; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; OUTCOME ASSESSMENT; OVARY CANCER; PAIN; PHASE 1 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RASH; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; SKIN TOXICITY; SURVIVAL PREDICTION; THROMBOCYTOPENIA; VOMITING; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; DISEASE FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; METABOLISM; MIDDLE AGED; MULTIMODAL IMAGING; OVARIAN NEOPLASMS; POSITRON EMISSION TOMOGRAPHY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ENDOMETRIAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; GLYCOLYSIS; HUMANS; MIDDLE AGED; MULTIMODAL IMAGING; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; SIROLIMUS; TOMOGRAPHY, X-RAY COMPUTED; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84919477496     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-014-0309-x     Document Type: Article

References (32)

1. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O’Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271–2281. doi:10.1056/NEJMoa066838
2. Gridelli C, Maione P, Rossi A (2008) The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist 13(2):139–147. doi:10.1634/theoncologist.2007-0171
3. Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, Eiermann W, Hess D, Morant R, Semiglazov V, Borner M, Salzberg M, Ostapenko V, Illiger HJ, Behringer D, Bardy-Bouxin N, Boni J, Kong S, Cincotta M, Moore L (2005) Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23(23):5314–5322
4. Fleming G, Ma C, Huo D, Sattar H, Tretiakova M, Lin L, Hahn O, Olopade FO, Nanda R, Hoffman P, Naughton MJ, Pluard T, Conzen S, Ellis M (2012) Phase II trial of temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat 136(2):355–363. doi:10.1007/s10549-011-1910-7
5. Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin AK, Alpaugh RK (2011) Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol 123(1):19–26
6. Takano M, Kikuchi Y, Kudoh K, Goto T, Furuya K, Kikuchi R, Kita T, Fujiwara K, Shiozawa T, Aoki D (2011) Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases. Int J Clin Oncol 16(5):605–609. doi:10.1007/s10147-010-0177-z
7. Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, Provencher DM, Gotlieb WH, Hoskins PJ, Ghatage P, Tonkin KS, Mackay HJ, Mazurka J, Sederias J, Ivy P, Dancey JE, Eisenhauer EA (2011) Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol 29(24):3278–3285
8. Piguet AC, Semela D, Keogh A, Wilkens L, Stroka D, Stoupis C, St-Pierre MV, Dufour JF (2008) Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. J Hepatol 49(1):78–87
9. Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M (2002) Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 62(21):6141–6145
10. Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, Mills GB, Meric-Bernstam F (2004) Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 10(20):7031–7042. doi:10.1158/1078-0432.CCR-04-0361
11. Tanaka M, Koul D, Davies MA, Liebert M, Steck PA, Grossman HB (2000) MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells. Oncogene 19(47):5406–5412
12. Jiang B-H, Liu L-Z (2008) Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updat 11(3):63–76. doi:10.1016/j.drup.2008.03.001
13. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19(14):3312–3322
14. Gordon AN, Tonda M, Sun S, Rackoff W (2004) Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95(1):1–8. doi:10.1016/j.ygyno.2004.07.011
15. Keller AM, Mennel RG, Georgoulias VA, Nabholtz J-M, Erazo A, Lluch A, Vogel CL, Kaufmann M, von Minckwitz G, Henderson IC, Mellars L, Alland L, Tendler C (2004) Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 22(19):3893–3901. doi:10.1200/jco.2004.08.157
16. Muggia FM, Blessing JA, Sorosky J, Reid GC (2002) Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a gynecologic oncology group study. J Clin Oncol 20(9):2360–2364
17. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247
18. Desar IME, van Herpen CML, van Laarhoven HWM, Barentsz JO, Oyen WJG, van der Graaf WTA (2009) Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev 35(4):309–321. doi:10.1016/j.ctrv.2008.12.001
19. Common Terminology Criteria for Adverse Events version 3.0. Available at: http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf.
20. Boellaard R, Oyen WJ, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, Arends B, Verzijlbergen FJ, Zijlstra J, Paans AM, Comans EF, Pruim J (2008) The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging 35(12):2320–2333
21. Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, Oyen WJ, Kotzerke J, Hoekstra OS, Pruim J, Marsden PK, Tatsch K, Hoekstra CJ, Visser EP, Arends B, Verzijlbergen FJ, Zijlstra JM, Comans EF, Lammertsma AA, Paans AM, Willemsen AT, Beyer T, Bockisch A, Schaefer-Prokop C, Delbeke D, Baum RP, Chiti A, Krause BJ (2010) FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 37(1):181–200. doi:10.1007/s00259-009-1297-4
22. Picus J (2012) Phase I study of DOXIL and temsirolimus in resistant solid mailgnancies. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00703170.
23. Thornton KA, Chen AR, Trucco MM, Shah P, Wilky BA, Gul N, Carrera-Haro MA, Ferreira MF, Shafique U, Powell JD, Meyer CF, Loeb DM (2013) A dose-finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma. Int J Cancer. doi:10.1002/ijc.28083
24. Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Park YC, Parekh TV, Poveda AM (2012) Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. Eur J Cancer 48(15):2361–2368
25. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A (2010) Pegylated liposomal Doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28(20):3323–3329
26. Steffensen KD, Waldstrom M, Pallisgard N, Lund B, Bergfeldt K, Wihl J, Keldsen N, Marth C, Vergote I, Jakobsen A (2012) Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: the PaLiDo Study, a phase II nonrandomized multicenter study. Int J Gynecol Cancer 3:3
27. Trafalis DT, Alifieris C, Krikelis D, Tzogkas N, Stathopoulos GP, Athanassiou AE, Sitaras NM (2012) Topotecan and pegylated liposomal doxorubicin combination as palliative treatment in patients with pretreated advanced malignant pleural mesothelioma. Int J Clin Pharmacol Ther 50(7):490–499
28. Ferrandina G, Ludovisi M, Lorusso D, Pignata S, Breda E, Savarese A, Del Medico P, Scaltriti L, Katsaros D, Priolo D, Scambia G (2008) Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 26(6):890–896
29. Kim RJ, Peterson G, Kulp B, Zanotti KM, Markman M (2005) Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers. Gynecol Oncol 97(2):374–378. doi:10.1016/j.ygyno.2004.12.057
30. Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J (2000) Phase 2 Trial of liposomal doxorubicin (40 mg/m2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 78(3):369–372. doi:10.1006/gyno.2000.5921
31. Weber WA, Figlin R (2007) Monitoring cancer treatment with PET/CT: does it make a difference? J Nucl Med 48(Suppl 1):36S–44S
32. Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, Casilla C, Fazzari M, Srivastava N, Yeung HW, Humm JL, Guillem J, Downey R, Karpeh M, Cohen AE, Ginsberg R (1999) Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging 2(3):159–171